Zobrazeno 1 - 10
of 46
pro vyhledávání: '"M J B, Taphoorn"'
Autor:
P B van der Meer, L Dirven, M Fiocco, M J Vos, M C M Kouwenhoven, M J van den Bent, M J B Taphoorn, J A F Koekkoek
Background About 10% of the glioma patients need antiepileptic drug (AED) tripletherapy due to refractory epilepsy. This study aimed to determine whether levetiracetam combined with valproic acid and clobazam (LEV+VPA+CLB), a commonly prescribed trip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::728ce6a76e2061453ce6f10e30d09971
https://hdl.handle.net/1887/3503886
https://hdl.handle.net/1887/3503886
Autor:
Günther Stockhammer, M. J. B. Taphoorn, Sietske A.M. Sikkes, Martin Klein, Linda Dirven, Florien W. Boele, Jonas Egeter, Bernard M. J. Uitdehaag, Christine Brannan, Quirien Oort, Neil K. Aaronson, Hitomi Sato, Monika Sztankay, I.M. Lips, Yoshitaka Narita, J.C. Reijneveld, Robin Grant, Andrea Talacchi
Publikováno v:
Neuro Oncol
BACKGROUND Neurocognitive deficits are common among brain tumour patients, and may impact on patient awareness of deficits in instrumental activities in daily life (IADL). This study aimed to examine differences between patient-reported and proxy-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee38b74774ef4b2abe7e4069716c3b38
https://europepmc.org/articles/PMC8427393/
https://europepmc.org/articles/PMC8427393/
Autor:
B Abecassis Schmitz, E Ercan, J de Bresser, L Dirven, M J B Taphoorn, M J P van Osch, J A F Koekkoek
Publikováno v:
Neuro-Oncology. 24:ii86-ii86
Background Chemical exchange saturation transfer (CEST) is an imaging technique that generates contrast based on proton exchange between water and a solute pool of interest. CEST is sensitive to molecules containing amine groups such as glutamate and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf66d8613aeb949bf64505153a8bc43f
https://doi.org/10.1093/neuonc/noac174.302
https://doi.org/10.1093/neuonc/noac174.302
Autor:
D van Dorth, J Jiang, B Schmitz-Abecassis, R J I Croese, M J B Taphoorn, M Smits, L Dirven, J de Bresser, M J P van Osch, J A F Koekkoek
Publikováno v:
Neuro-Oncology. 24:ii85-ii85
Background Perfusion MRI by Arterial Spin Labeling (ASL) and Dynamic Susceptibility Contrast (DSC) has shown its potential for differentiating tumor progression from pseudo-progression in glioblastoma patients. The ASL scans can be affected by arteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26162ca972b6f2e6b7e0e8051566bca0
https://doi.org/10.1093/neuonc/noac174.296
https://doi.org/10.1093/neuonc/noac174.296
Autor:
Q Oort, J Koekkoek, N K Aaronson, F W Boele, C Brannan, A Capela, M Hjermstad, M Klein, I Lips, Y Narita, A Pace, D Petranovic, J Pichler, J C Reijneveld, H Sato, C Seidel, O Shamieh, S A M Sikkes, A Talacchi, B M J Uitdehaag, T Urbanic, T Young, M J B Taphoorn, L Dirven
Publikováno v:
Neuro-Oncology. 24:ii3-ii3
Background Brain tumour patients often have neurocognitive deficits which can result in problems with activities in daily living that are cognitively complex. Currently, no valid and reliable brain tumour-specific instrument to measure these instrume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12d73b048690394051f273820662af47
https://doi.org/10.1093/neuonc/noac174.007
https://doi.org/10.1093/neuonc/noac174.007
Autor:
M P van Opijnen, C M S Tesileanu, L Dirven, P B van der Meer, M M J Wijnenga, A J P E Vincent, M L D Broekman, H J Dubbink, J M Kros, S G van Duinen, M Smits, P J French, M J van den Bent, M J B Taphoorn, J A F Koekkoek
Publikováno v:
Neuro-Oncology. 24:ii74-ii74
Background IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or +7/−10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered gliob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d55f188ae828f154324d98404dd8eb
https://doi.org/10.1093/neuonc/noac174.258
https://doi.org/10.1093/neuonc/noac174.258
Autor:
L Dirven, Marion Smits, S G van Duinen, Pim J. French, M. J. van den Bent, Johan M. Kros, Johan A F Koekkoek, C M S Tesileanu, Hendrikus J. Dubbink, M J B Taphoorn
Publikováno v:
Neuro Oncol
BACKGROUND Recently, isocitrate dehydrogenase wildtype (IDHwt) lower grade gliomas (LGGs) that have a telomerase reverse transcriptase (TERT) promoter mutation and/or gain of chromosome 7 combined with loss of chromosome 10 and/or epidermal growth fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6ee684a3b8ecd2ced24edfb13ad697d
https://europepmc.org/articles/PMC6795591/
https://europepmc.org/articles/PMC6795591/
Autor:
M. van der Meulen, J.K. Doorduijn, M J B Taphoorn, Katerina Bakunina, M. J. van den Bent, Samar Issa, Jacoline E C Bromberg, L Dirven
Publikováno v:
Neuro Oncol
BACKGROUND Data on the impact of treatment with Rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma (PCNSL) patients are scarce. To determine the net clinical benefit of a new treatment, analyzing the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb9c8f61904dcc30c1a4849d2f12e52
https://doi.org/10.1093/neuonc/noz126.044
https://doi.org/10.1093/neuonc/noz126.044
Autor:
Carolyn C. Gotay, E. M. Basch, C. Quinten, W.S. Ashley, Rajeshwari Sridhara, Ingolf Griebsch, Laura Lee Johnson, Galina Velikova, Michael Koller, M. J. B. Taphoorn, Martine Piccart, Elisabeth Piault-Louis, Francesca Martinelli, Mogens Grønvold, Jaap C. Reijneveld, Katherine M. Soltys, Jeff A. Sloan, Madeleine King, Laurence Collette, Daniel William O'Connor, Kathy Oliver, Alicyn Campbell, S. Christoph, Daniel C. Malone, Amylou C. Dueck, Madeline Pe, Melanie Calvert, Lien Dorme, Nancy Devlin, A. Bottomley, C. Coens, Sandra A. Mitchell, Kim Cocks, Charles S. Cleeland, Henning Flechtner, Paul G. Kluetz, Jammbe Z. Musoro
Publikováno v:
Value in Health. 22:S525
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e54a076cd37dde003f5f75ec6eba52d
https://doi.org/10.1016/j.jval.2019.09.649
https://doi.org/10.1016/j.jval.2019.09.649
Autor:
Laurens V. Beerepoot, B. van der Holt, Bas Jasperse, J. F. De Groot, René M. Vernhout, M. J. B. Taphoorn, Marleen Smits, M. J. van den Bent, Renske Gahrmann, Walter Taal
Publikováno v:
Europe PubMed Central
Purpose: Response assessment in brain tumors is currently done with the 2D Response Assessment in Neuro-Oncology (RANO) criteria. However, bevacizumab-treated patients may show pseudoresponse on contrast enhanced T1w- (T1w+C), and more infiltrative g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5655add88207ad1c624084af2d4ec380
https://europepmc.org/articles/PMC5782528/
https://europepmc.org/articles/PMC5782528/